Check for updates

OPEN ACCESS

EDITED BY Huangen Ding, Louisiana State University, United States

REVIEWED BY Zhi-Gang Jeff Qian, Shanghai Jiao Tong University, China Jian Wang, University of Georgia, United States

*CORRESPONDENCE Eung-Soo Kim ⊠ eungsoo@inha.ac.kr

SPECIALTY SECTION

This article was submitted to Microbial Physiology and Metabolism, a section of the journal Frontiers in Microbiology

RECEIVED 27 October 2022 ACCEPTED 23 February 2023 PUBLISHED 15 March 2023

CITATION

Kim H-J, Seo S-Y, Park H-S, Ko J-Y, Choi S-S, Lee SJ and Kim E-S (2023) Engineered *Escherichia coli* cell factory for anthranilate over-production. *Front. Microbiol.* 14:1081221. doi: 10.3389/fmicb.2023.1081221

COPYRIGHT

© 2023 Kim, Seo, Park, Ko, Choi, Lee and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Engineered *Escherichia coli* cell factory for anthranilate over-production

Hye-Jin Kim¹, Seung-Yeul Seo², Heung-Soon Park¹, Ji-Young Ko¹, Si-Sun Choi¹, Sang Joung Lee² and Eung-Soo Kim¹*

¹Department of Biological Sciences and Bioengineering, Inha University, Incheon, Republic of Korea, ²STR Biotech Co., Ltd., Gangwon-do, Republic of Korea

Anthranilate is a key platform chemical in high demand for synthesizing food ingredients, dyes, perfumes, crop protection compounds, pharmaceuticals, and plastics. Microbial-based anthranilate production strategies have been developed to overcome the unstable and expensive supply of anthranilate via chemical synthesis from non-renewable resources. Despite the reports of anthranilate biosynthesis in several engineered cells, the anthranilate production yield is still unsatisfactory. This study designed an Escherichia coli cell factory and optimized the fed-batch culture process to achieve a high titer of anthranilate production. Using the previously constructed shikimate-overproducing E. coli strain, two genes (aroK and aroL) were complemented, and the trpD responsible for transferring the phosphoribosyl group to anthranilate was disrupted to facilitate anthranilate accumulation. The genes with negative effects on anthranilate biosynthesis, including pheA, tyrA, pabA, ubiC, entC, and trpR, were disrupted. In contrast, several shikimate biosynthetic pathway genes, including aroE and tktA, were overexpressed to maximize glucose uptake and the intermediate flux. The rationally designed anthranilate-overproducing E. coli strain grown in an optimized medium produced approximately 4g/L of anthranilate in 7-L fed-batch fermentation. Overall, rational cell factory design and culture process optimization for microbial-based anthranilate production will play a key role in complementing traditional chemical-based anthranilate production processes.

KEYWORDS

Anthranilate, cell factory design, *Escherichia coli*, metabolic engineering, genome editing

Introduction

Anthranilate is a key metabolite involved in the aromatic amino acid biosynthetic pathway and a vital metabolite used as a precursor for the synthesis of many valuable aromatic compounds in bacteria, fungi, and plants (Jiang and Zhang, 2016; Averesch and Krömer, 2018; Santos-Sánchez et al., 2019). These aromatic amino acids, such as L-phenylalanine (L-Phe), L-tyrosine (L-Tyr), and L-tryptophan (L-Trp), which are typically synthesized *via* the shikimate pathway, are used as precursors for the production of various secondary metabolites essential for plant growth, and also critical building blocks for protein biosynthesis in microorganisms (Weaver and Herrmann, 1997; Tzin and Galili, 2010; Jiang and Zhang, 2016; Santos-Sánchez et al., 2019).

The shikimate pathway generates chorismate through sequential enzymatic reactions, starting with a condensation reaction of phosphoenolpyruvate (PEP) produced *via* the glycolic pathway and erythrose-4-phosphate (E4P) produced *via* the pentose phosphate pathway (Jiang and Zhang, 2016; Averesch and Krömer, 2018; Santos-Sánchez et al., 2019). In *E. coli*, chorismate



enhanced steps through target gene overexpression. Dashed arrows represent two or more steps. G6P; glucose-6-phosphate, F6P; fructose-6-phosphate, G3P; glyceraldehyde-3-phosphate, PEP; phosphoenolpyruvate, PYR; pyruvate, ACoA; acetyl-CoA, X5P; xylulose-5-phosphate, R5P; ribose-5-phosphate, S7P; sedoheptulose-7-phosphate, E4P; erythrose-4-phosphate, F6P; fructose-6-phosphate, DAHP; 3-deoxy-D-arabisoheptulosanate-7-phosphate.

is converted to prephenate, anthranilate, aminodeoxychorismate, isochorismate, and x-hydroxybenzoate in five enzymatic reactions used in the production of various aromatics, including aromatic amino acids (Figure 1, Dosselaere and Vanderleyden, 2001; Gosset, 2009; Koma et al., 2012; Noda et al., 2016).

Anthranilate is an aromatic acid used as a platform chemical for the production of food ingredients, dyes, perfumes, crop protection compounds, pharmaceutical compounds, and plastics (Askham, 1992; Yadav and Krishnan, 1998; Wiklund and Bergman, 2006; Balderas-Hernández et al., 2009; Bahia et al., 2011; Shafiq et al., 2011; Haynes et al., 2012; Chambers et al., 2013; Gao et al., 2013; Loque and Weniger, 2013; Sun et al., 2013; Walsh et al., 2013; Kuepper et al., 2015; Lee et al., 2019; Luo et al., 2019). In addition, anthranilate inhibits biofilm formation in a wide range of bacteria, which is expected to expand the industrial application of anthranilate (Li et al., 2017). Since shikimate was recently reported to stimulate hair growth through cell proliferation of human dermal papilla cells and outer root sheath cells (Choi M. et al., 2019; Choi N. et al., 2019), potential value of shikimate pathway metabolites including anthranilate also continues to expand.

Currently, anthranilate production is based on chemical synthesis using petroleum-derived precursors, such as benzene, which is an energy-intensive process limited by toxic byproduct production (Balderas-Hernández et al., 2009; Kuepper et al., 2015). Therefore, attempts are being made to produce anthranilate from renewable resources in an environmentally friendly manner, and microbial-based anthranilate production is being suggested as an alternative. According to previous studies, up to 14 g/L of anthranilate production was reported through the fed-batch fermentation of recombinant *E. coli* strain W3110 *trpD*9923/pJLBaroG^{fbr}tktA, and 1.5 g/L of anthranilate production was achieved using *Pseudomonas putida* KT2440 strain (*P. putida* Δ *trpDC*/

pSEVA234_*aroG*^{D146N}_*trpE*^{S40F}G), respectively (Balderas-Hernández et al., 2009; Kuepper et al., 2015; Fernández-Cabezón et al., 2022). A genome-engineered *Corynebacterium glutamicum* YTM5 strain harboring pEKGH produced 26.40 g/L of anthranilate in glucose minimal medium (Luo et al., 2019). An engineered yeast strain was also reported to produce 0.56 g/L of anthranilate (Kuivanen et al., 2021).

Previous studies published the world's highest shikimate highproduction *E. coli* strain. The current study attempted to develop an anthranilate high-production strain by optimizing the shikimate-toanthranilate pathway based on a secured shikimate high-production strain (Lee et al., 2021). The present study performed additional engineering to produce anthranilate starting from the shikimateoverproducing strain. The further re-designed anthranilate-producing *E. coli* strain produced approximately 4g/L of shikimate in 7-L fed-batch fermentation. These results suggest that the artificial cell factory design for the shikimate-overproducing strain would be valuable for constructing a microorganism-based strain for producing aromatic compounds in industrial quantities.

Materials and methods

Bacterial strains, media, and culture conditions

Table 1 lists all the bacterial strains used in this study. *E. coli* DH5 α was used as the cloning host, and *E. coli* AB2834 was used as the metabolite production host. All *E. coli* strains were grown in Luria-Bertani (LB) medium at 30 or 37°C with the appropriate antibiotics. Small-scale cultivation and fed-batch fermentation for anthranilate

TABLE 1 Strains and plasmids used in this study.

Strain or plasmid	Characteristics	Sources or reference
Escherichia coli AB2834		
Inha215	AB2834 Δ tyrR Δ ptsG Δ pykA Δ lacI::Plac_aroB_aroD_Plac_aroG_aroF_Plac_ppsA_galP Δ aroL Δ aroK Δ shiA / pPoppA-aroE-tktA	Lee et al. (2021)
Inha250	Inha215△aroL::ParoL-aroL_ParoK-aroK△trpD△pheA&tyrA	This study
Inha251	Inha215△aroL::ParoL-aroL_ParoK-aroK△trpD△pabA	This study
Inha252	Inha215△aroL::ParoL-aroL_ParoK-aroK△trpD△ubiC	This study
Inha253	Inha215△aroL::ParoL-aroL_ParoK-aroK△trpD△entC	This study
Inha254	Inha215 <u></u> <i>aroL::ParoL-aroL_ParoK-aroK</i> <u><i>trpD</i></u> <i>pheA&tyrA</i> <i>_pabAubiC_entC</i>	This study
Inha255	Inha215△aroL::ParoL-aroL_ParoK-aroK△trpD△pheA&tyrA △pabA△ubiC△entC△menF	
Inha256	Inha254 Δ aroL::PJ23119_aroL&aroK Δ trpR Δ aroE _{AB2834} ::PoppA_aroE _{K-12} Δ tktA::PJ23119_tktA	This study
Inha257	Inha256 <u>_pabB</u> _menD_aroA::PoppA_aroA&aroC	This study
Plasmid		
pCas	repA101(Ts) kan Pcas-cas9 ParaB-Red lacIq Ptrc-sgRNA-pMB1	Addgene (Jiang and Zhang, 2016)
pTargetF	pMB1 aadA sgRNA-cadA	Addgene (Jiang and Zhang, 2016)
pTarget-PJ23119_aroL-aroK	pTargetF containing sgRNA of <i>aroL</i> , constitutive J23119 promoter, coupled <i>aroL</i> & <i>aroK gene</i> and its homologous arms	This study
pTarget- <i>trpR</i>	pTargetF containing sgRNA of <i>trpR</i> and its homologous arms	This study
pTarget-PoppA_aroE	pTargetF containing sgRNA of <i>aroE</i> , <i>oppA</i> promoter, <i>aroE</i> gene, and its homologous arms	This study
pTarget-PJ23119_tktA	pTargetF containing sgRNA of <i>tktA</i> , constitutive <i>J23119</i> promoter, <i>tktA</i> gene, and its homologous arms	This study
pTarget- <i>trpD</i>	pTargetF containing sgRNA of <i>trpD</i> and its homologous arms	This study
pTarget-pheA-tyrA	pTargetF containing sgRNA of pheA and its homologous arms	This study
pTarget- <i>pabA</i>	pTargetF containing sgRNA of <i>pabA</i> and its homologous arms	This study
pTarget- <i>pabB</i>	pTargetF containing sgRNA of <i>pabB</i> and its homologous arms	This study
pTarget-entC	pTargetF containing sgRNA of <i>entC</i> and its homologous arms	This study
pTarget-ubiC	pTargetF containing sgRNA of <i>ubiC</i> and its homologous arms	This study
pTarget-menD	pTargetF containing sgRNA of menD and its homologous arms	This study
pTarget-PoppA_aroA-aroC	pTargetF containing sgRNA of <i>aroA</i> , <i>oppA</i> promoter, coupled <i>aroA</i> & <i>aroK</i> gene and its homologous arms	This study

production were conducted, as described previously (Lee et al., 2021). For small-scale cultivation in a 24-well culture plate, a single colony was inoculated in 1.3 ml LB medium at 30°C for 15 h. The culture broth was inoculated with 1% (v/v) in the same medium at 30°C for 15 h. The secondary culture broth was inoculated in 1.3 ml of *E. coli* production medium (EPM) at 30°C for 4 days. The miniature cultivation was performed using a humidity chamber set to 80% humidity and 200 rpm.

Construction of plasmids and strains

 Table 1 lists the constructed plasmids, and Supplementary Table 1

 presents all primer pairs used in this study. The CRISPR/Cas system

was utilized for targeted gene editing. The two-plasmid system, in which the cas9 gene and a targeting N_{20} sequence directing it to the gene loci of interest, were separated in the pCas and pTargetF, respectively. N_{20} sequences followed by the PAM were designed by the web tool, CHOPCHOP.¹ The homologous DNA fragments to the upstream and downstream regions of the target gene were amplified with primer sets. The fragment, including the N_{20} sequence and guide RNA scaffold, was also amplified. These fragments were cloned into *SpeI/HindIII*-digested pTargetF based on the In-Fusion Cloning method (TaKaRa, Japan). For gene overexpression, PJ23119 or PoppA

¹ https://chopchop.cbu.uib.no

promoter sequence and target gene amplified with the specific primers were cloned with homologous DNA fragments and N₂₀ sequence into pTargetF simultaneously. Genome editing and plasmid curing were performed, as described previously (Jiang and Zhang, 2016). The transformants were verified by colony PCR and DNA sequencing. TransStart[®] FastPfu Fly DNA polymerase (Transgen Biotech., China) and SapphireAmp[®] Fast PCR Master Mix (TaKaRa, Japan) were used to amplify the target-specific fragments and colony PCR, respectively.

Fed-batch fermentation

For fed-batch fermentation, the single colony was inoculated in 5 ml LBG (25g/L LB broth and 20g/L glucose) medium at 30°C, 200 rpm for 12 h. The primary culture broth was inoculated with 1% (v/v) in 20 ml same medium at 30°C for 6 h. The secondary culture broth was then inoculated with 1% (v/v) in a 7L fermenter. The production culture was performed using the modified PB4-md5 medium. The modified PB4-MD5 medium included the following: 30g/L glucose, 10g/L glycerol, 37.125g/L yeast extract, 5.25g/L KH₂PO₄, 1g/L MgSO₄•7H₂O, 2ml/L trace metals, and 200µg/L thiamine hydrochloride. The feeding medium was composed of 600 g/L glucose, 100 g/L yeast extract, 20 g/L MgSO₄•7H₂O, and 5 ml/L trace metal. Phosphate was not added to the feeding medium to regulate cell growth. The feeding medium was supplied using a peristaltic pump when glucose was depleted. The pH was adjusted with 10 N NaOH or 3 M HCL at 7.0, and the DO level was maintained above 40% by controlling the rpm, aeration, and feeding rates (Lee et al., 2021).

Anthranilate and shikimate pathway metabolites analyses

The cultured broth was centrifuged at 15,000 RPM for 5 min. The supernatant was filtered using a 0.22 μ m syringe filter (Rainbow PVDF membrane filter) and stored at -20° C. The concentrations of anthranilate and the shikimate pathway metabolites were determined by high-performance liquid chromatography (HPLC) using a Zorbax SB-Aq column (4.6 × 250 mm, Agilent, USA). The mobile phase was 0.1% trifluoroacetic acid (TFA) in 30% MeOH, and the flow rate was 0.5 ml/min. Anthranilate and shikimate pathway metabolites were detected at 330 and 214 nm, respectively.

Results

Redesign of anthranilate biosynthetic pathway in shikimate-overproducing *E. coli*

The shikimate over-producing strain (Inha215) obtained in a previous study (Lee et al., 2019) was an engineered *E. coli* cell factory strain designed to maximize the accumulation of shikimate by deleting six genes (*tyrR*, *ptsG*, *pykA*, *shiA*, *aroL*, and *aroK*) from the chromosome and by overexpressing eight genes (*aroB*, *aroD*, *aroF*, *aroG*, *galP*, *ppsA*, *aroE*, and *tktA*; Table 1). An attempt was made to re-activate the shikimate pathway by compensating for the shikimate kinase genes (*aroL* and *aroK*) involved in the conversion of shikimate to shikimate-3-phosphate. Using the CRISPR/Cas9

system, two genes, *aroL* and *aroK*, were complemented to be expressed under their own-promoter regulation. Unlike the shikimate over-producing Inha 215 strain, which could not synthesize the essential aromatic amino acids, this complemented strain was activated by shikimate kinases and grew well in minimal medium (Supplementary Figures 1A,B).

Anthranilate is a metabolite produced by converting chorismate by an anthranilate synthase (TrpEG) in the shikimate pathway (Figure 1), which is then converted to an anthranilate-phosphate precursor by anthranilate phosphoribosyltransferase, TrpD (Xie et al., 2003; Merino et al., 2008; Balderas-Hernández et al., 2009). Therefore, by deleting trpD in the presence of aroL and aroK, anthranilate was accumulated successfully without other metabolic processes (Supplementary Figures 1C,D). In addition, there are several enzymes involved in bypass routes for chorismate to be converted to other metabolites, including bifunctional chorismate mutase/prephenate dehydratase (encoded by pheA and tyrA), anthranilate synthase (encoded by *trpEG*), p-aminobenzoate synthase (encoded by *pabAB*), isochorismate synthase (encoded by *menF* and entC), chorismate lyase (encoded by ubiC) (Figure 1, Dosselaere and Vanderleyden, 2001; Sprenger, 2007; Noda et al., 2016). The genes involved in the bypass routes mentioned above were removed sequentially to maximize the accumulation of chorismite as much as possible. Based on the shikimate over-producing Inha215 strain, Inha250 with the pheA and tyrA genes removed, Inha251 with the pabA and tyrA gene removed, Inha252 with the entC gene removed, and Inha254 strain with the pheA, tyrA, pabA, entC, and ubiC gene removed were generated sequentially (Supplementary Figures 1C,D). Finally, approximately 18.7 mg/L of anthranilate was produced into the Inha254 strain (Supplementary Figure 1E). The Inha255 strain, which also removed *menF* encoding isochorismate synthase in *E. coli*, was also developed, but unlike the Inha254 strain, anthranilate production was not carried out (Supplementary Figure 1E).

Redesign of the shikimate pathway genes to enhance anthranilate production

Five key shikimate pathway genes, such as trpR, aroE, tktA, aroL, and aroK, were engineered further to maximize anthranilate production using the Inha254 strain constructed above. First, a wellknown shikimate pathway transcriptional regulator gene, trpR, was deleted from the Inha254 chromosome, and the aroE was integrated into the Inha254 chromosome under the control of strong oppA promoter (Supplementary Figures 2, 3; Gu et al., 2016). Second, to increase the erythrose-4-phosphate (E4P) pool, one of the essential precursors of the shikimate pathway, the *tktA* involved in the pentose phosphate pathway was over-expressed under the control of the strong promoter J23119 (Supplementary Figure 4; Shen et al., 2012; Lee et al., 2021). Third, the aroL and arolK genes were coupled translationally and expressed under the control of the strong promoter J23119 (Supplementary Figure 5). The strain called Inha256, which was optimized for these five genes (trpR, arooE, tktA, and aroL&aroK) produced 56.8 mg/L of anthranilate, which is approximately three times higher production yield than that of Inha254 (Figure 2).

Moreover, to minimize the chorismite bypass pathways, *menF* encoding 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1- carbosylate synthase and *pabB* encoding ρ -aminobenzoate



synthase subunit involved in the chorismite metabolism to either isochorismate and p-aminobenzoate, respectively (Supplementary Figure 6). In addition, two genes, *aroA* and *aroC*, were translationally coupled and overexpressed under the control of strong *oppA* promoter (Supplementary Figure 7). Approximately 74.6 mg/L of anthranilate was produced in the strain described above (called Inha 257; Figure 2).

Fed-batch fermentation for anthranilate production

Although the anthranilate production yield of the Inha257 strain increased 1.3 fold compared to the Inha256 strain, the cell growth of Inha257 also increased 1.1 fold, suggesting that the redesign of the four genes (*menD*, *fabB*, *aroA*, and *aroC*) attempted in the Inha257 had a positive effect on cell growth rather than anthranilate production optimization (Figure 2). Occasionally, the inha257 strain was inconsistent in both cell growth and anthranilate productivity compared to the Inha256 strain (data not shown), so that the subsequent fed-batch experiment was conducted using the Inha256 strain.

Cell growth increased rapidly after 8h of incubation. The stationary phase was reached after 18h in a 7-L fed-batch fermentation of Inha256 strain (Figure 3). Subsequently, cell growth slightly increased after 27h of culture with a lower feeding rate, but showed constant cell growth until 72h when the culture was terminated. The production yield of anthranilate in the Inha256 strain gradually increased after 10h of culture and reached the maximum after 60h of culture, producing approximately 4g/L in the recombinant *E. coli* (Figure 3). Interesting, however, 18g/L of anthranilate was once observed depending on the culture and feeding conditions (Supplementary Figure 8).

Discussion

This study attempted to construct an anthranilate highproduction recombinant *E. coli* strain through genetic and metabolic engineering. Based on the shikimate over-producing strain obtained in previous studies, the shikimate pathway was reinforced, and the metabolic pathway was redesigned to accumulate the main precursor, chorismate, in the biosynthesis pathway of anthranilate. In strengthening the shikimate pathway, the efficient expression of *aroE* encoding a shikimate dehydrogenase, is believed to be an important step. Unlike previous studies that expressed *aroE* in a high-copy vector (Lee et al., 2021), this study applied the CRISPR/Cas9 system to generate a plasmid-free expression system by designing *aroE* to be expressed stably on *E. coli* chromosome under the control of a powerful OppA promoter.

In addition, all chorismate bypass routes, except the anthranilate biosynthesis pathway, were blocked to accumulate chorismate, a key precursor of an anthranilate. Interestingly, when menF encoding isochorismate synthase was removed, virtually no anthranilate and shikimate production was observed, suggesting that MenF interacted with other shikimate pathway-related enzymes. The additional removal of menD encoding a 2-succinyl-5-enolpyruvyl-6-hydroxy-3-carbosylate synthase and pabB encoding a p-aminobenzoate synthase subunit were pursued to maximize the accumulation of menaquinone and polyacids from the chorismate. Surprisingly, there were no significant changes in the chorismate accumulation (Supplementary Figure 9). Therefore, it was confirmed that the removal of the aforementioned five genes, such as pheA, tyrA, pabA, ubiC, entC, and trpR, was the best option to maximize the accumulation of anthranilate. Although isoenzyme, AroL, is expected to act as the main shikimate kinase by showing a substrate affinity approximately 100 times higher than AroK. Moreover, the activity of AroL is reported to be greatly affected by the type and concentration of divalent cation (Huang et al., 1975; DeFeyter and Pittard, 1986). Therefore, additional anthranilate over-production could be achieved through AroL enzyme engineering and kinetics optimization.

In conclusion, the rationally designed anthranilateoverproducing *E. coli* strain grown in an optimized medium produced approximately 4 g/L of anthranilate in 7-L fed-batch



FIGURE 3

Fed-batch fermentation for anthranilate production of Inha256 in a 7l bioreactor. Time course of RPM, DO concentration, pH and anthranilate production yield were indicated, respectively. The feeding (indicated as an arrow) was started with 0.1323ml/min at 16h and changed with 0.1701ml/ min, 0.1512ml/min and 0.0567ml/min at 36, 39, and 84h, respectively (Left). The feeding was started with 0.1323ml/min at 16h and changed with 0.0945 and 0.1323ml/min at 30 and 36h, respectively (Right).

fermentation. Overall, rational cell factory design and culture process optimization for microbial-based anthranilate production will play a vital role in complementing traditional chemical-based anthranilate production processes.

Development (project no. PJ01563901)" Rural Development Administration.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

SL and E-SK designed the research. H-JK, S-YS, H-SP, J-YK, and S-SC performed the experiments, as well as data collection and analysis. H-JK and J-YK performed genetic engineering. S-YS and H-SP performed medium optimization and fermentation. H-JK, J-YK, S-SC, SL, and E-SK wrote and edited the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was carried out with the support of "Cooperative Research Program for Agriculture Science and Technology

Conflict of interest

S-YS and SL are employed by STR Biotech Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2023.1081221/ full#supplementary-material

References

Askham, L. R. (1992). "Efficacy of methyl anthranilate as a bird repellent on cherries, blueberries and grapes" in *Proceeding of the 15th vertebrate Pest conference*. eds. J. E. Borrecco and R. E. Marsh (Davis, CA: University of California), 137–141.

Averesch, N. J. H., and Krömer, J. O. (2018). Metabolic engineering of the Shikimate pathway for production of aromatics and derived compounds—present and future strain construction strategies. *Front. Bioeng. Biotechnol.* 6:32. doi: 10.3389/fbioe.2018.00032

Bahia, M. S., Gunda, S. K., Gade, S. R., Mahmood, S., Muttineni, R., and Silakari, O. (2011). Anthranilate derivatives as TACE inhibitors: docking based CoMFA and CoMSIA analyses. *J. Mol. Model.* 17, 9–19. doi: 10.1007/s00894-010-0695-7

Balderas-Hernández, V. E., Sabido-Ramos, A., Silva, P., Cabrera-Valladares, N., Hernández-Chávez, G., Báez-Viveros, J. L., et al. (2009). Metabolic engineering for improving anthranilate synthesis from glucose in *Escherichia coli*. *Microb. Cell Factories* 8:19. doi: 10.1186/1475-2859-8-19

Chambers, A. H., Evans, S. A., and Folta, K. M. (2013). Methyl anthranilate and gamma-decalactone inhibit strawberry pathogen growth and achene germination. *J. Agric. FoodChem.* 61, 12625–12633. doi: 10.1021/jf404255a

Choi, M., Choi, S. J., Jang, S., Choi, H. I., Kang, B. M., Hwang, S., et al. (2019). Shikimic acid, a mannose bioisostere, promotes hair growth with the induction of anagen hair cycle. *Sci. Rep.* 9:17008. doi: 10.1038/s41598-019-53612-5

Choi, N., Kim, W. S., Oh, S. H., and Sung, J. H. (2019). HB-EGF improves the hair regenerative potential of adipose-derived stem cells via ROS generation and Hck phosphorylation. *Int. J. Mol. Sci.* 21:122. doi: 10.3390/ijms21010122

DeFeyter, R. C., and Pittard, J. (1986). Purification and properties of shikimate kinase II from Escherichia coli K-12. J. Bacteriol. 165, 331–333. doi: 10.1128/jb.165.1.331-333.1986

Dosselaere, F., and Vanderleyden, J. (2001). A metabolic nod in action: chorismateutilizing enzymes in microorganism. *Crit. Rev. Microbiol.* 27, 75–131. doi: 10.1080/20014091096710

Fernández-Cabezón, L., Bosch, B. R., Kozaeva, E., Gurdo, G., and Nikel, P. I. (2022). Dynamic flux regulation for high-titer anthranilate production by plasmid-free, conditionally-auxotrophic strains of pseudomonas Putida. *Metab. Eng.* 73, 11–25. doi: 10.1016/j.ymben.2022.05.008

Gao, X., Jiang, W., Jiménez-Osés, G., Choi, M. S., Houk, K. N., Tang, Y., et al. (2013). An iterative, bimodular nonribosomal peptide synthetase that converts anthranilate and tryptophan into tetracyclic asperlicins. *Chem. Biol.* 20, 870–878. doi: 10.1016/j. chembiol.2013.04.019

Gosset, G. (2009). Production of aromatic compounds in bacteria. Curr. Opin. Biotechnol. 20, 651-658. doi: 10.1016/j.copbio.2009.09.012

Gu, P., Su, T., Wang, Q., Liang, Q., and Qi, Q. (2016). Tunable switch mediated shikimate biosynthesis in an engineered non-auxotrophic Escherichia coli. *Sci. Rep.* 6:29745. doi: 10.1038/srep29745

Haynes, S. W., Gao, X., Tang, Y., and Walsh, C. T. (2012). Assembly of asperlicin peptidyl alkaloids from anthranilate and tryptophan: a two-enzyme pathway generates heptacyclic scaffold complexity in asperlicin E. J. Am. Chem. Soc. 134, 17444–17447. doi: 10.1021/ja308371z

Huang, L., Montoya, A. L., and Nester, E. W. (1975). Purification and characterization of shikimate kinase enzyme activity in Bacillus subtilis. *J. Biol. Chem.* 250, 7675–7681. doi: 10.1016/S0021-9258(19)40868-5

Jiang, M., and Zhang, H. (2016). Engineering the shikimate pathway for biosynthesis of molecules with pharmaceutical activities in *E. coli. Curr. Opin. Biotechnol.* 42, 1–6. doi: 10.1016/j.copbio.2016.01.016

Koma, D., Yamanaka, H., Moriyoshi, K., Ohmoto, T., and Sakai, K. (2012). Production of aromatic compounds by metabolically engineered *Escherichia coli* with an expanded shikimate pathway. *Appl. Environ. Microbiol.* 78, 6203–6216. doi: 10.1128/AEM.01148-12

Kuepper, J., Dickler, J., Biggel, M., Behnken, S., Jäger, G., Wierckx, N., et al. (2015). Metabolic engineering of *Pseudomonas putida* KT2440 to produce anthranilate from glucose. *Front. Microbiol.* 6:1310. doi: 10.3389/fmicb.2015.01310 Kuivanen, J., Kannisto, M., Mojzita, D., Rischer, H., Toivari, M., and Jäntti, J. (2021). Engineering of *Saccharomyces cerevisiae* for anthranilate and methyl anthranilate production. *Microb. Cell Factories* 20:34. doi: 10.1186/s12934-021-01532-3

Lee, H. L., Kim, S. Y., Kim, E. J., Han, D. Y., Kim, B. G., and Ahn, J. H. (2019). Synthesis of methylated anthranilate derivatives using engineered strains of *Escherichia coli*. *J. Microbiol. Biotechnol.* 29, 839–844. doi: 10.4014/jmb.1904.04022

Lee, H. N., Seo, S. Y., Kim, H. J., Park, J. H., Park, E., Choi, S. S., et al. (2021). Artificial cell factory design for shikimate production in *Escherichia coli*. J. Ind. Microbiol. Biotechnol. 48:kuab043. doi: 10.1093/jimb/kuab043

Li, X. H., Kim, S. K., and Lee, J. H. (2017). Anti-biofilm effects of anthranilate on a broad range of bacteria. *Sci. Rep.* 7:8604. doi: 10.1038/s41598-017-06540-1

Loque, D., and Weniger, A. G. E. (2013). Host cells and methods for producing cinnamoyl anthranilate and analogs thereof. US20130078683, A1.

Luo, Z. W., Cho, J. S., and Lee, S. Y. (2019). Microbial production of methyl anthranilate, a grape flavor compound. *Proc. Natl. Acad. Sci. U. S. A.* 116, 10749–10756. doi: 10.1073/pnas.1903875116

Merino, E., Jensen, R. A., and Yanofsky, C. (2008). Evolution of bacterial trp operons and their regulation. *Curr. Opin. Microbiol.* 11, 78-86. doi: 10.1016/j. mib.2008.02.005

Noda, S., Shirai, T., Oyama, S., and Kondo, A. (2016). Metabolic design of a platform *Escherichia coli* strain producing various chorismate derivatives. *Metab. Eng.* 33, 119–129. doi: 10.1016/j.ymben.2015.11.007

Santos-Sánchez, N. F., Salas-Coronado, R., Hernández-Carlos, B., and Villanueva-Cañongo, C. (2019). "Shikimic acid pathway in biosynthesis of phenolic compounds" in *Plant physiological aspects of phenolic compounds*. eds. M. Soto-Hernández, R. García-Mateos and M. Palma-Tenango (London: IntechOpen)

Shafiq, M., Zia-Ur-Rehman, M., Khan, I. U., Arshad, M. N., and Khan, S. A. (2011). Synthesis of novel anti-bacterial 2,1-benzothiazine2,2-dioxides derived from methylanthranilate. *J. Chil. Chem. Soc.* 56, 527–531. doi: 10.4067/S0717-97072011000100001

Shen, T., Liu, Q., Xie, X., Xu, Q., and Chen, N. (2012). Improved production of tryptophan in genetically engineered Escherichia coli with TktA and PpsA overexpression. *J. Biomed. Biotechnol.* 2012:605219. doi: 10.1155/2012/605219

Sprenger, G. A. (2007). From scratch to value: engineering *Escherichia coli* wild type cells to the production of L-phenylalanine and other fine chemicals derived from chorismate. *Appl. Microbiol. Biotechnol.* 75, 739–749. doi: 10.1007/ s00253-007-0931-v

Sun, X., Lin, Y., Huang, Q., Yuan, Q., and Yan, Y. (2013). A novel muconic acid biosynthesis approach by shunting tryptophan biosynthesis via anthranilate. *Appl. Environ. Microbiol.* 79, 4024–4030. doi: 10.1128/AEM.00859-13

Tzin, V., and Galili, G. (2010). New insights into the shikimate and aromatic amino acids biosynthesis pathways in plants. *Mol. Plant* 3, 956–972. doi: 10.1093/mp/ssq048

Walsh, C. T., Haynes, S. W., Ames, B. D., Gao, X., and Tang, Y. (2013). Short pathways to complexity generation: fungal peptidyl alkaloid multicyclic scaffolds from anthranilate building blocks. *ACS Chem. Biol.* 8, 1366–1382. doi: 10.1021/cb4001684

Weaver, L. M., and Herrmann, K. M. (1997). Dynamics of the shikimate pathway in plants. *Trends Plant Sci.* 2, 346–351. doi: 10.1016/S1360-1385(97)84622-5

Wiklund, P., and Bergman, J. (2006). The chemistry of anthranilic acid. *Curr. Org. Synth.* 3, 379–402. doi: 10.2174/157017906777934926

Xie, G., Keyhani, N. O., Bonner, C. A., and Jensen, R. A. (2003). Ancient origin of the tryptophan operon and the dynamics of evolutionary change. *Microbiol. Mol. Biol. Rev.* 67, 303–342. doi: 10.1128/MMBR.67.3.303-342.2003

Yadav, G. D., and Krishnan, M. S. (1998). An ecofriendly catalytic route for the preparation of perfumery grade methyl anthranilate from anthranilic acid and methanol. *Org. Process. Res. Dev.* 2, 86–95. doi: 10.1021/op980074j